Please note that following on from information provided to NICE by the company in May 2016, the appraisal of Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma [ID609] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 609 |
| Referral date | 01 May 2012 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Bijal Joshi |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in May 2016, the appraisal of Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma [ID609] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 May 2016 | Suspended. The Department of Health has asked the Institute to conduct an appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma. The Institute has now been informed by the company that it will no longer be pursuing a licensing application for bendamustine in this indication. Therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any developments. |
| 4 February 2013 | The manufacturer is unable to provide an evidence submission for this appraisal by 22 February 2013. The appraisal is suspended whilst we consider the next steps. |
For further information on our processes and methods, please see our CHTE processes and methods manual